Pilot study of radiotherapy with misonidazole in head and neck cancer.
Twenty-nine patients with advanced carcinoma of the upper air and food passages were treated by radiotherapy using a 10-fraction three-week scheme, giving 1.2 g/m2 of misonidazole 4 h before each treatment. Complete tumour regression was observed in 24 of the patients, and at a nine-month follow-up the local tumour control rate is 60%. Sixteen patients developed evidence of peripheral neuropathy. A prospective random controlled trial is recommended to confirm the apparently improved local tumour control from the use of misonidazole in this study.
D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy*; D004334:Drug Administration Schedule; D005260:Female; D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008920:Misonidazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009422:Nervous System Diseases / Q000139:chemically induced; D009593:Nitroimidazoles / Q000627:therapeutic use*; D010865:Pilot Projects; D011879:Radiotherapy Dosage
D009593:Nitroimidazoles; D008920:Misonidazole